<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Johnson-Johnson-US4781601046">Johnson &amp; Johnson</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">19 days ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260902938660/en/Johnson-Johnson-to-Participate-in-the-Deutsche-Bank-2026-Healthcare-Summit/">Johnson &amp; Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit</a>
    </div>

      <div class="me-0 me-md-5">
        NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson &amp; Johnson (NYSE: JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17th, 2026. Management will participate in a Fireside Chat at 12:00 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson &amp; Johnson&#39;s Investor Relations website at www.investor.jnj.com. An archived edition of...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Johnson-Johnson-US4781601046">Johnson &amp; Johnson</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">25 days ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/china-approves-jjs-oral-psoriasis-pill-says-drugmaker-2026-08-27/">China approves J&amp;J&#39;s oral psoriasis pill, says drugmaker</a>
    </div>

      <div class="me-0 me-md-5">
        China&#39;s ​drug regulator has approved Johnson &amp; Johnson&#39;s oral ‌pill for psoriasis, the company said on Thursday, intensifying competition in the world&#39;s second-largest pharmaceutical market ​with rivals including Bristol Myers Squibb and ​AbbVie.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Johnson-Johnson-US4781601046">Johnson &amp; Johnson</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">28 days ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/fda-approves-imaavy-nipocalimab-aahu-as-first-ever-treatment-for-warm-autoimmune-hemolytic-anemia-waiha-representing-a-landmark-advancement-for-patients-302858778.html">FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients</a>
    </div>

      <div class="me-0 me-md-5">
        IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood cells, leading to severe anemia and debilitating fatigue The approval is based on the pivotal Phase 2/3 study ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Johnson-Johnson-US4781601046">Johnson &amp; Johnson</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">28 days ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-expands-approval-jjs-drug-rare-blood-disorder-2026-08-24/">US FDA expands approval for J&amp;J&#39;s drug for rare blood disorder</a>
    </div>

      <div class="me-0 me-md-5">
        The U.S. ​Food and ‌Drug Administration ​has ​approved the expanded ⁠use ​of ​Johnson &amp; Johnson&#39;s drug to ​treat ​a rare blood ‌disorder, ⁠the company said ​on ​Monday.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Johnson-Johnson-US4781601046">Johnson &amp; Johnson</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">28 days ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260824893836/en/Louisiana-Jury-Issues-10-Million-Verdict-in-Talc-Related-Mesothelioma-Case-Against-Johnson-Johnson/">Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson &amp; Johnson</a>
    </div>

      <div class="me-0 me-md-5">
        DALLAS--(BUSINESS WIRE)--Texas trial law firm Dean Omar Branham Shirley, LLP (DOBS) has secured a $10 million jury verdict in a mesothelioma case brought on behalf of the family of Lynne Roy, a Louisiana woman who died in 2020 after developing the deadly lung disease mesothelioma following decades of exposure to talc products. DOBS attorneys Danny Kraft and Darren McDowell led the trial team re...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Johnson-Johnson-US4781601046">Johnson &amp; Johnson</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">CNBC</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about 2 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.cnbc.com/2026/08/06/jim-cramer-5-investing-themes-stocks-to-buy.html">Jim Cramer highlights 5 investing themes — and the stocks to buy for each</a>
    </div>

      <div class="me-0 me-md-5">
        CNBC&#39;s Jim Cramer said earnings season reinforced five investing themes he thinks will produce the market&#39;s best buying opportunities. He highlighted stocks to buy for each theme, including Capital One, Ralph Lauren, Lam Research, CrowdStrike, Goldman Sachs and Eli Lilly.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Johnson-Johnson-US4781601046">Johnson &amp; Johnson</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about 2 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260804385778/en/Johnson-Johnson-to-Participate-in-the-2026-Wells-Fargo-Healthcare-Conference/">Johnson &amp; Johnson to Participate in the 2026 Wells Fargo Healthcare Conference</a>
    </div>

      <div class="me-0 me-md-5">
        NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson &amp; Johnson (NYSE: JNJ) will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9th, 2026. Management will participate in a Fireside Chat at 11:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson &amp; Johnson&#39;s Investor Relations website at www.investor.jnj.com. An archived edition ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Johnson-Johnson-US4781601046">Johnson &amp; Johnson</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about 2 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260804327747/en/Johnson-Johnson%E2%80%99s-Executive-Vice-President-Jennifer-Taubert-to-Retire-Tom-Cavanaugh-Appointed-EVP-Worldwide-Chairman-Innovative-Medicine-Effective-September/">Johnson &amp; Johnson&#39;s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September</a>
    </div>

      <div class="me-0 me-md-5">
        NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson &amp; Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson &amp; Johnson. Under her leadership, the Company&#39;s Innovative Medicine business grew to more than $60 billion in annual revenue ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Johnson-Johnson-US4781601046/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>